HK inno.N signs CMO contract to produce clinical trial drugs for stem cell-derived organoid treatments

By Lim Chang-won Posted : November 2, 2022, 13:39 Updated : November 2, 2022, 13:39

[Courtesy of HK inno.N ]

SEOUL -- HK inno.N, a bio-health company in South Korea, will carry out the consignment production of clinical trial drugs for stem cell-derived organoid treatments under development by Cell in Cells, a domestic bio company which has a pipeline of stem cell-derived regenerative organoid treatments for various diseases. 

An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic micro-anatomy. Organoids are derived from cells from a tissue, embryonic stem cells, or induced pluripotent stem cells. Organ structures have been recapitulated using organoids for tissue engineering studies and cancer therapy testing.

This is the first consignment production contract since HK inno.N opened a research center dedicated to cell gene therapy in Hanam, a southern satellite city of Seoul, in 2020. "We will diversify our business structure through active CDMO and CMO in the field of cell gene therapy and strengthen our competitiveness as a bio-health company," an unnamed HK inno.N official said in a statement on November 2. 

The contract development and manufacturing organization (CDMO) is a concept of consignment development and production beyond contract manufacturing organization (CMO) that serves other companies to provide comprehensive services.
기사 이미지 확대 보기